Northland Securities Predicts MiMedx Group FY2027 Earnings

MiMedx Group, Inc (NASDAQ:MDXG) – Equities research analysts at Northland Securities decreased their FY2027 earnings per share (EPS) estimates for MiMedx Group in a research report issued to clients and investors on Tuesday, January 20th. Northland Securities analyst C. Byrnes now forecasts that the company will post earnings per share of $0.20 for the year, down from their previous forecast of $0.45. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share.

A number of other research analysts also recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Lake Street Capital decreased their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. Mizuho decreased their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, December 17th. Finally, Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Trading Up 1.7%

MiMedx Group stock opened at $5.42 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. MiMedx Group has a 1 year low of $5.13 and a 1 year high of $9.30. The firm’s 50-day moving average is $6.62 and its 200-day moving average is $6.88. The company has a market cap of $802.70 million, a P/E ratio of 20.07 and a beta of 1.57.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.08. The firm had revenue of $113.73 million for the quarter, compared to analysts’ expectations of $94.74 million. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently modified their holdings of MDXG. CWM LLC lifted its holdings in shares of MiMedx Group by 63.8% during the second quarter. CWM LLC now owns 4,857 shares of the company’s stock valued at $30,000 after purchasing an additional 1,892 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in MiMedx Group by 1,808.4% during the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock valued at $46,000 after buying an additional 7,107 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of MiMedx Group in the third quarter worth about $54,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of MiMedx Group in the third quarter worth about $84,000. Finally, Allianz Asset Management GmbH purchased a new position in shares of MiMedx Group in the third quarter worth approximately $82,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total transaction of $432,586.00. Following the completion of the sale, the insider owned 236,982 shares in the company, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.70% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.